The surgical management of male breast cancer: Time for an easy access national reporting database? by Staruch, RMT et al.
lable at ScienceDirect
Annals of Medicine and Surgery 9 (2016) 41e49Contents lists avaiAnnals of Medicine and Surgery
journal homepage: www.annalsjournal .comCase reportThe surgical management of male breast cancer: Time for an easy
access national reporting database?
Robert M.T. Staruch a, *, Maral J. Rouhani b, Mohammed Ellabban c
a Guys & St Thomas's Hospital NHS Trust, London, United Kingdom
b North Central Thames Deanery Basildon University Hospital, Nethermayne, Basildon, SS16 5NL, United Kingdom
c Heart of England NHS Trust, United Kingdomh i g h l i g h t sMale breast cancer is extremely rare with an incidence of less than 1% of all breast cancers.
We report a series of seven cases of male breast cancer encountered over three years, evaluating patient demographics, treatment and outcomes.
 Review of these patients highlighted a lack of consensus on the optimal surgical strategy for their management.
 The paper discusses the plausible options for surgical reconstruction of male breast cancer defects.
 The authors advocate an easy access national reporting database to improve large scale data collection and surgical intervention.a r t i c l e i n f o
Article history:
Received 4 April 2016
Received in revised form
6 June 2016
Accepted 7 June 2016
Keywords:
Male
Breast
Cancer
Breast reconstruction* Corresponding author. Department of Surgery &
versity College London, The Royal Free Hospital, Pon
United Kingdom.
E-mail addresses: robmtstaruch@doctors.o
maralrouhani@gmail.com (M.J. Rouhani), M
(M. Ellabban).
http://dx.doi.org/10.1016/j.amsu.2016.06.001
2049-0801/© 2016 The Author(s). Published by Elsev
creativecommons.org/licenses/by-nc-nd/4.0/).a b s t r a c t
Introduction: Male breast cancer is extremely rare with an incidence of less than 1% of all breast cancers.
Literature reports a peak of incidence at roughly 71 years of age. Management currently follows the same
clinical pathways as female breast cancer as a general rule.
Methods: A retrospective search for all patients who were referred and diagnosed with male breast
cancer at our centre was undertaken. Patients notes were then explored for demographics, histological
staging, multidisciplinary team meeting outcome and treatment.
A literature search including the search terms ‘Male Breast Cancer AND Surgery’ or ‘Male Breast Cancer
AND Experience’ were used. Non English language articles, or those without abstracts were excluded.
Results: Seven patients were reviewed over 3 years (2006e2009). Mean agea was 69 years and mean
lesion size was 15 mm. Histology was invasive ductal carcinoma for all patients. All patients were ER
receptor positive. Two patients were HER2 positive. Five patients were offered mastectomy. One patient
refused treatment. In follow up at 36 months there were 3 recurrences. 1 patient was lost to follow up.
There were 3 mortalities.
The literature search identiﬁed 72 articles. Articles were subdivided into those that discussed the surgical
management of male breast cancer (n ¼ 8), articles that discussed male breast cancer as podium pre-
sentations or posters with no full text article publication (n ¼ 13) and ﬁnally full text publications of case
experience of male breast cancer (n ¼ 21).
Discussion: We report a series of seven cases of male breast cancer encountered over three years,
evaluating patient demographics as well as treatment and outcomes. In our series patients were
managed with mastectomy. New evidence is questioning the role of mastectomy against breast
conserving surgery in male patients. Furthermore there is a lack of reporting infrastructure for national
data capture of the beneﬁts of surgical modalities. Literature review highlights the varied clinical
experience between units that remains reported as podium presentation but not published. The
establishment of an online international reporting registry would allow for efﬁcient analysis of surgicalInterventional Science, Uni-
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R.M.T. Staruch et al. / Annals of Medicine and Surgery 9 (2016) 41e4942outcomes to improve patient care from smaller single centres. This would facilitate large scale meta
analysis by larger academic surgical centres.
© 2016 The Author(s). Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Male breast cancer represents around 1% of all breast cancers
worldwide and evidence shows that it is on the rise [1,2]. The rarity
of male breast cancer makes conducting a prospective trial difﬁcult
but not impossible. Progress in this area has been made with col-
laborations between Europe and north America to launch the
EORPT-BIG-NABGS prospective trial on male breast cancer. The
pitfall of this paucity of male focused research and outcome data is
a lack of tailored treatment regimes. This is as a result of several
confounding factors, namely the low incidence, the lack of co-
ordinate reporting of new cases and outcomes. The focus of
recent male breast cancer research has been in understanding the
importance of molecular subtyping in outcomes. Furthermore data
from metastatic male breast cancer has supported the practice of
utilizing female protocols to treat male patients.
Juxtaposed against the research into the hormonal and genetic
interplay in male breast cancer, there is a lack of surgical outcome
data for this patient group. Surgical management traditionally in-
volves the use of a radical mastectomy to aggressively en bloc
tumour resection. Despite the improvements in our understanding
of the biohormonal markers of male breast cancer, little has
changed or been added to the surgical armantarium. The aim of this
case series is to review our centres 7 case experience of male breast
cancer and to discuss the potential reasons behind a lack of surgical
evolution in this disease. Finally we propose a solution to improve
the change of this surgical change.
2. Methods
A retrospective review was conducted over a 3 year period of
hospital records for patients diagnosed and treated at our centre for
Male breast cancer. Patient's notes were reviewed for de-
mographics, histological staging, multidisciplinary team meeting
outcome and treatment.
A literature review was conducted to search for all presented
and published data on the surgical management of male breast
cancer and comparative single centre experience. Search terms
‘Male Breast Cancer AND Experience’ or Male Breast Cancer AND
Surgery’ were used. Included articles for review were those that
presented case experience of male breast cancer or discussed its
surgical management. Podium presentations or posters were
included. Publications were tabulated and reviewed. Articles that
concerned biohormonal investigation of male breast cancer, adju-
vant therapy treatment were excluded from further review or non
English language were excluded.
3. Results
3.1. Case series
Our unit reviewed a total of 7 cases over a three-year period
(2006e2009) of which 4 were diagnosed as male breast cancer. The
mean age of our population was 69 years with a range of 47e93
years. 2 patients had gynaecomastia prior to diagnosis. 5 patients
(71%) presented with a lump in the subareolar region, whilst 2
patients (29%) presented with an ulcer on the areola that wasclinically suspicious of skin cancer and referred to dermatology for
formal biopsy and diagnosis. One patient's breast lesion was diag-
nosed on immunohistochemistry as a prostate metastatic second-
ary. 4 patients had their lesion located on the right breast, whilst 3
patients presented on the left breast. Two patients (29%) had pre-
vious malignant disease other than breast cancer prior to presen-
tation; one had previous bladder cancer, whilst another had a
previous prostate primary. Table 1 highlights the outcomes of these
patients.
The mean lesion size on histological examination was 15 mm.
All histology (100%) showed invasive ductal carcinoma, of which
only 1 patient had vascular invasion. All patients (100%) were ER
receptor positive, whilst 2 patients (29%) were HER2 positive. Our
histopathology department did not routinely test for progesterone
receptor status, and this was not documented in the pathology
records. One patient was CK7 negative, whilst the remainders were
CK7 positive (86%). Table 2 summarizes these histological ﬁndings.
Mortality in our group was three (43%), of which 1 refused
treatment. One patient was referred to another unit due to geog-
raphy. 5 patients were offered simple mastectomy with sentinel
lymph node biopsy. Three patients were offered axillary node
clearance for positive lymph nodes of which one declined. 1 patient
received no treatments (on his request) as mentioned. 1 patient
received primary hormonal treatment only (medically unﬁt). The
chemotherapy regime in our unit was 6 cycles of Cyclophospha-
mide, 5 Flurouracil and Methotrexate. One patient received a cycle
of epirubacin to augment his chemotherapy treatment. One patient
received radiotherapy. All patients were advised of Tamoxifen
tablets for 5 years, whilst the two patients with Her-2 positive
histochemistry were offered Herceptin therapy.
Treatment outcomes were varied; patients were followed up for
36 months during which one patient was lost to follow-up due to
desire to be referred to another unit. 3 patients had no recurrence
during follow-up; two patients had local spread and one had spinal
metastases. Three patients died of their disease state.3.2. Literature review
Literature search yielded 72 results. The results were subdivided
into three cohorts. The ﬁrst was conference abstracts for posters or
podium presentations. Thirteen abstracts were reviewed that dis-
cussed single or multi centre experience of male breast cancer
(Table 3). The largest case series in this group was 13,457 patients
from the US National Cancer Data Base. The smallest groups were of
16 patients. The second group was articles that direction discussed
the surgical management or published case experience of surgical
techniques for male breast cancer (Table 4). Eight articles were
included in this group. The largest cohort in this group reviewed
the poor compliance and outcomes of lumpectomy with adjuvant
therapy and partial mastectomy in 6039 male patients. The third
group reviewed full text case experience publications, of which 21
were available for review (Table 5). This reﬂected 1390 patients in
total. The largest cohort in this group was 244 patients, The mean
number of patients presented in publication was 66 patients per
publication. Mean age for this group was 55.5 years. Mean 5 e year
overall survival was 51.44%.
Table 1
Patient demographics, treatment pathway and outcomes. ANC e Axillary Node Clearance (þ ¼ Yes,  ¼ No). Tx e Treatment. F/U e Follow Up.
Patient 1 2 3 4 5 6 7
Presentation Lump in
sub areolar
Hard focal lump,
inner areola.
Red Crusted
plaque over
nipple and
areola
destruction.
Right breast lump Right Breast Lump Lump inch or two from Lateral left areola
Gynaecomastia No Yes No No No Yes No
Treatment Mastectomy,
Chemotherapy,
Tamoxifen
Nil Primary
Hormonal
Therapy Tx
Offered Mastectomy þ
ANC - Declined
Mastectomy þ ANC.
Mastectomy, SLNB,
LN þ Ve, ANC Chemo,
Tamoxifen
Mastectomy
Chemotherapy
Radiotherapy
Herceptin
Tamoxifen
Mastectomy,
SNLB & LN þ VE &
ANC, Chemotherapy
Follow Up Referred on.
Note CK7
Negative
(Unusual)
Immunohistochemistry
later revealed this was
prostate Metastasis
Palliative Recurrence lower pole
of right nipple. Bone
Metastasis T12
2 Years F/U Clear.
On Tamoxifen
2 Years.
No recurrence
2 Years No recurrence.
On Tamoxifen
Outcome Alive Deceased Alive Alive Alive Alive Alive
Table 2
Histochemistry of male breast cancer lesions for patients. Gene Amp e Gene Ampliﬁcation.
Patient 1 2 3 4 5 6 7
Age 77 80 93 47 63 53 75
Grade 2 2 3 3 1 2 3
Side Right Left Right Left Right Left Right
Invasion Yes Yes Yes Yes Yes Yes Yes
Type Ductal Ductal Ductal Ductal Ductal Ductal Ductal
Vascular invasion No No No No No No Yes
Size 11 mm 11mm Deep Hard Mass 15mm 9mm 22mm 22mm
ER status Positive Positive Positive Positive Positive Positive Positive
HER status Negative Negative Negative Negative ? HER2 þve Gene Amp eve,
immunhistochemistry stain 2 þ ve
Positive Negative
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This data highlights the experience of a small oncoplastic breast
units experience with locally treating male cancer over 3 years. It
demonstrates the low incidence of male breast cancer presenting to
loco-regional centres. These results demonstrate the need for a
national and international reporting mechanism in order to collate
large cohorts of data in order to improve understanding and out-
comes. Our study found 100% of the patients in the case series were
oestrogen-receptor (ER) positive; this signiﬁcant correlation has
also been widely documented [1,2], alongside the paucity of triple-
negative male breast cancer and on average 5% reported rate of
HER2-positive cancers [3]. Our study also found that 100% of the
patients had invasive ductal carcinoma, consistent with wide-
spread evidence of a low rate of in-situ disease, estimated at 11%
[2,4,5]. The propensity to present as an invasive ductal carcinoma
with estrogen positive receptor status correlates with the ﬁndings
of our literature review. (Tables 3 and 5).
Compared to the literature our case experience is relatively
small. It size correlates with other published case series from local
or regional centres who treated male breast cancer. Our cohort was
predominately grade 2 lesions less than 2 cm in diameter with all
cases ER positive. This correlates with previously published case
series. Review of the literature identiﬁes that the majority of pub-
lished experiences come from regional or national patient series
(Tables 3 and 5). Datasets presented as posters or presentations
appeared to have a narrower range of patient sizes (Table 3). The
largest cohort found in the literature was 13,000 patients, which
had the lowest rate of surgical treatment, at 33% [6]. This was the
lowest rate amongst the cohorts presented at conference. The
progression towards breast conserving surgery cannot be seen in
these series where the rate of modiﬁed radical mastectomyremained at 96.80% in a series from 2014.
Whilst international collaborations are underway to undertake
large scale prospective data collection on male breast cancer, more
needs to be done to allow small centres to document their expe-
rience. This would facilitate the meta-analysis by larger academic
centres. The Helsinki declaration outlines the need for research
reporting in order to facilitate transparency and outcome reporting.
Despite the Helsinki declaration, presenters of abstracts at inter-
national meetings are not obliged to record their data into a data
registry. The online research registry is one such tool for the
registration of clinical patient trials for all disciplines. The signiﬁ-
cance of small centres experience would be magniﬁed if centres
could bank their clinical experience data in a registry for further
analysis. Such a platform has been trialled by Orthopaedic surgeons
who used a hub and spoke system to conduct a national hip
arthroplasty audit [7]. Encouraging local hospitals to collate their
case outcomes in a preset excel spreadsheet, the hub centre (Oxford
University) could analyse each departments data individually and
compare it both to other centres and the national means. This
technique has also been trialled for national audit and clinical trials
in reconstructive surgery (RSTN) [8]. The success and robustness of
regional data input into national databases for prospective analysis
has also been demonstrated in the orthopaedic implant registry [9]
and the vascular network database [10]. In both theses examples it
has enabled surgical outcome data and an improvement in service
delivery regionally.
The international collaboration between The EORTC [11], Breast
International Group (BIG), North American Breast Cancer Groups
(NABCG), Borstkanker Onderzoeksgroup Nederland, Ireland Coop-
erative Oncology Research Group, Schweizerisches Arbeitsge-
meinschaft Klin. Krebsforschung, and Swedish Association of Breast
Oncologists has already facilitated a global retrospective data
Table 3
Male breast cancer experience presented at international conferences.
Author Year Journal/Meeting Patients Age Histo Hormone status 5YS e Overall survival Surgery Mastect
1 Kaushik (1) 2012 Male Breast Cancer e University Hospitals of
Leicester Experience Male Breast Cancer e
University Hospitals of Leicester Experience
57 71.5 Invasive ductal
carcinoma
97.60% ER þ 55.60% 41 38
2 Sedighi (2) 2014 Clinicopathologic characteristics of male breast
cancer: A report of 21 cases at a radiotherapy
centre in hamadan, Iran
21 49.2 Invasive ductal 76.1% ER þ NA NA NA
3 Stevens (3) 2012 Efﬁcacy of Aromatase Inhibitors in Male Breast
Cancer n a Single Centre Experience
64 NA NA NA NA NA NA
4 Serarslan (4) 2015 Male Breast Cancer: 20 Years Experience of a
Tertiary Hospital from the Middle Black Sea
Region of Turkey
16 59.8 Inﬁltrative
ductal ca
93.80% ER þ 68% 62% NA
5 Calil (5) 2014 Male breast cancer: Epidemiological study in
patients attended in three academic hospitals in
S~ao Paulo
35 35 Invasive ductal
carcinoma
88.50% ER þ 78.30% 96.80% 96.90%
6 Mueller (6) 2010 Male Breast Cancer - 25 Years Single Institution
Experience
61 62 NA NA 66% 41 patients MRM. NA
7 Ghiotto (7) 2005 Male breast cancer: our experience from 1990
to 2004
48 60 87.50% 75% of ER þ/PR þ NA 97% 97% - mastectomy,
1 conservative surgery
8 Walsh (8) 2005 Adjuvant chemotherapy in stage II node
positive male breast cancer.
31 61 NA 74% ER þ, 61% PR þ NA 100% NA
9 Giordano (9) 2003 Male Breast Cancer: The MD Anderson
experience.
156 59 85% ER þ, 71% PR þ 86% NA NA
10 Polo (10) 2001 Long term outcome of male breast cancer. A
single institution experience
21 65 19pts inﬁltrative
ductal ca
NA 36% NA NA
11 Mohler (11) 1997 Treatment and Prognosis of Male breast cancer:
the Heidelberg experience
16 55 14/16 invasive
ductal ca%
64% ER 82% PR NA MRM in all. 9/15
Axillary
lymphonodectomy,
1 pt bilateral MBC
9/15 Axillary
lymphonodectomy,
1 pt bilateral MBC
12 Greif (12) 2013 Gender Differences in Breast Cancer: Analysis of
13,000 Male Breast Cancers From the National
Cancer Data Base
13,457 NA ER 88.3%, PR 76.8 74% 33% partial
mastectomy
13 Kwong (13) 2013 The American society of Breast surgeons 142 64.87 94.5% ER þ, 84.8
PR þ, 60.5 HER2 þ
73.10% 76.1% mastectomy
1. Kaushik M, Oliveira-Cunha M, Shokuhi S. Male breast cancer: a single centre experience and current evidence. Breast J. 2014; 20(6):674e5.
2. Sedighi A, Akbari Hamed E, Mohammadian K, Maddah A, Kalaghchi B, Behnod S. P0160 Clinicopathologic characteristics of male breast cancer: A report of 21 cases at a radiotherapy centre in hamadan, Iran. European Journal of
Cancer.50:e54.
3. Stevens R. 261 Efﬁcacy of Aromatase Inhibitors in Male Breast Cancer n a Single Centre Experience. European Journal of Cancer.48:S118eS9.
4. Alparslan S. Male Breast Cancer: 20 Years Experience of a Tertiary Hospital from the Middle Black Sea Region of Turkey. Asian Paciﬁc Journal of Cancer Prevention. 2015; 16(15):6673e9.
5. Marcelo Calil EA, Felipe Cruz, Damila Trufelli, Jo~ao Carlos Sampaio Goes, Auro del Giglio. Male breast cancer: Epidemiological study in patients attended in three academic hopistals in S~ao Paulo. World Cancer Congress 2014.
6. Mueller A, Rehm H, Eckert F, Hehr T, Bamberg M. Male Breast Cancer - 25 Years Single Institution Experience. International Journal of Radiation Oncology  Biology  Physics. 78(3):S218.
7. Ghiotto C BM, D'andrea E, Da Silva Amona E, Rigon A, Monfardini S. Male breast cancer: our experience from 1990 to 2004. 2005. p. 130.
8. Walshe JM VU, Berman AW, Steinberg SM, Llpman ME, Anderson WF, Swain SM. Adjuvant Chemotherapy in stage II node positive male breast cancer. Breast Cancer Research and Treatments. 2005; 94(1).
9. Giordano SH PG, Garcia SM, Middleton LP, Buzdar AU, Hortobagyi GN. Male breast cancer: The MD Anderson experience with adjuvant therapy. Breast Cancer Research and Treatments. 2003; 82(1):S1eS184.
10. Polo E, Velilla C, Mayordomo J, Polo S, Filipovich E, Isla D et al. Long-term outcome of male breast cancer. A single institution experience. European Journal of Cancer.37:S170.
11. M€ohler M, Rensing K, Gutzier F, Grischke EM, Wallwiener D, Bastert G et al. Treatment and prognosis of male breast cancer: The Heidelberg experience. European Journal of Cancer.33:S156.
12. Greif J PC, Klimberg S, Bailey L, Zuraek M, editor Gender Differences in Breast Cancer: Analysis of 13,000 Male Breast Cancers From the National Cancer Data Base. The American Society of Breast surgeons,; 2013; Pheonix.
13. Ava KwongWC, OscarWKMang, Connie HNWong, Hong Kong Breast Cancer, Research Group SCL. Male Breast Cancer in Hong Konge A Population-Based Analysis of Epidemiological Characteristics, Overall, Cancer-Speciﬁc,
and Disease-Free Survival in 1997e2006. The American society of Breast surgeons; Pheonix2013.
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Table 4
Presentations or publications discussing the surgical management of male breast cancer.
Author Title Year Journal/Meeting Pts 5YS - overall Surgery WLE or lumpectomy
1 Nguyen (1) Demand for breast-conserving surgery among
male breast cancer patients
2012 The American Society
of Breast Surgeons
9 NA 4 patients requested breast
conserving surgery.
2 Lanitis (2) Breast conserving surgery with preservation fo
the nipple areola complex as a feasible and safe
approach in male breast cancer: a case report
2008 Journal of medical
case reports
1 Breast conserving surgery with axillary clearance, hormone
therapy and radiotherapy, chemo.
3 Uematsu (3) Two-step approach for the operation of male
breast cancer: Report of a case at high risk for
surgery
1998 Kobe Journal of
Medical Sciences
1 Simple mastectomy under LA then 1 month later a radical
mastectomy for breast cancer.
4 Treves (4) the treatment of cancer, especially inoperable
cancer of the male breast by ablative surgery
(orchiectomy, adrenalectomy and
hyphysectomy and hormone therapy
(oestrogens and corticosteroids). An analysis of
42 patients
1959 Cancer 162 NA Mastectomy, orchiectomy, adrenelectomy.
5 Zaenger (5) Mastectomy vs Breast Conservation for Early-
Stage Male Breast Cancer: A Comparison of
Oncologic Outcomes - vs breast conservation for
early stage male breast cancer: A comparison of
oncologic outcomes.
2016 Oncology 1777 MRM 97.3, BCT 100% 83% SM or MRM, 17% BCS, 46% receive PORT to complete tx.
6 lanitis (2) Breast conserving surgery with preservation of
the nipple-areola complex as a feasible and safe
approach in male breast cancer: a case report.
2008 Journal of Medical
Case Reports
1 case
7 Cloyd (6) Poor compliance with breast cancer treatment
guidelines in men undergoing breast-
conserving surgery
2013 Breast Cancer
Research and
Treatment
6039 66.10% 77.80% 59.2% lumpectomy,
39.4% nodal positive
8 Cloyd (7) Outcomes of Partial mastectomy in male breast
cancer patients: analysis of SEER, 1983e2009
2013 Ann Surg Oncol 4707 þ 727
(Mastect/Lump)
87.3% lumpectomy,
87.7% Mastectomy,
overall survival 66
(lumpectomy)%,
70.1 mastectomy
86.80% 13.20%
9 Al-Kalla (8) Breast total male breast reconstruction with fat
grafting.
2007 Breast 7 6 pts SNLB, 5 Axillary
node clearance,
7 Lumpectomy/Wide
Excision
NA NA
Golshan M (9) Breast conservation for male breast carcinoma.
Breast
2015 PRS Global Open 1 SNLB eve, Mastectomy NA NA
1. Trang Nguyen MC. Demand for Breast-Conserving Surgery Among Male Breast Cancer Patients. The American Society of Breast Surgeons; Pheonix, Arizona 2012.
2. Lanitis S, Filippakis G, Al Mufti R, Hadjiminas DJ. Breast conserving surgery with preservation of the nipple-areola complex as a feasible and safe approach in male breast cancer: a case report. Journal of Medical Case Reports.
2008; 2:126.
3. Uematsu M, Okada M, Ataka K. Two-step approach for the operation of male breast cancer: report of a case at high risk for surgery. Kobe J Med Sci. 1998; 44(4):163e8.
4. Treves N. The treatment of cancer of the male breast, especially inoperable, by ablative surgery (orchiectomy, adrenalectomy, hypophysectomy) and the hormone therapy with estrogens and corticosteroids: an analysis of 42
patients. Acta Unio Int Contra Cancrum. 1959; 15:1169e78.
5. Zaenger D, Rabatic BM, Dasher B, Mourad WF. Is Breast Conserving Therapy a Safe Modality for Early-Stage Male Breast Cancer? Clin Breast Cancer. 2015.
6. Cloyd JM, Hernandez-Boussard T, Wapnir IL. Poor compliance with breast cancer treatment guidelines in men undergoing breast-conserving surgery. Breast Cancer Res Treat. 2013; 139(1):177e82.
7. Cloyd JM, Hernandez-Boussard T, Wapnir IL. Outcomes of partial mastectomy in male breast cancer patients: analysis of SEER, 1983e2009. Ann Surg Oncol. 2013; 20(5):1545e50.
8. Al-Kalla T, Komorowska-Timek E. Breast total male breast reconstruction with fat grafting. Plast Reconstr Surg Glob Open. 2014; 2(11):e257.
9. Golshan M, Rusby J, Dominguez F, Smith BL. Breast conservation for male breast carcinoma. Breast. 2007; 16(6):653e6.
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Table 5
Published full text articles discussing case experience of male breast cancer.
Author Title Year Journal Pts Age Histo Hormone status 5YS - overall Surgery Mastect WLE or lumpectomy
Shah P (1) Clinicopathological study
of male breast carcinoma:
24 years of experience
2009 Ann Saudi
Med. 2009
JuleAug;
29 (4):
288e293.
32 NA
Pemmaraju
N (2)
Retrospective review of
male breast cancer
patients: analysis of
tamoxifen-related
side-effects
2011 Ann Oncol
(2011)
126 61 54.7% Stage II 97% NA NA NA NA
Eldin A
Elgohary
S (3)
Male Breast Cancer;
Experience with 6
cases
2010 2010; 8 (10)
Nature and
Science
6 60 All invasive
ductal carcinomas
71.40% NA - tx failure
in 1 pt at 6 months.
5/6 Modiﬁed
radical mastectomy
NA
Rai B (4) Breast cancer in males:
A PGIMER experience
2005 J Cancer Res
Ther - March
2005 - vol 1
e Issue 1
30 57.13 Invasive
ductal ca n ¼ 28
40% 28 25 3
Soliman (5) A retrospective analysis
of survival and prognotstic
factors of male breast
cancer from a single centre
2014 BMC Cancer 69 58 invasive ductal n ¼ 29 46.60% All underwent
modiﬁed radical
mastectomy with
axillary lymph
node dissection
NA NA
Ahmed (6) Management and
outcomes of male breast
cancer in Zaria, Nigeria
2012 International
journal of
breast cancer
2012
57 59 Invasive ductal
ca 88%
57 - 100% 22.80% 49
Yildirim (7) Male breast cancer: 22 year
experience
1998 European
Journal of
Surgical
Oncology
24 6 548-552
121 60 87.6% invasive
ductal ca.
NA 73% 121 96 25
Ngoo (8) Male breast cancer:
experience from a
malaysian tertiary
centre
2009 Singore Med J
50 (5) 519
6 64.5 5/6 inﬁltrative
ductal ca
06-Jun NA 66.7% total
mastectomy
NA
Masci (9) Clinicopathological
and immunohistocheimcal
characteristics in male
breast cancer: a
retrospective case series.
2015 Oncologist
Jun2015 vol
20. 6 586-592
97 65 All invasive
ductal ca
96.7% oest/prog
92.3%
68.10% NA nA NA
Gogia (10) Male Breast cancer: a
single institute experience
2015 Indian journal
of cancer
76 59 96% Invasive
ductal ca
78% ER Positive OS rate at 3 years
was 95%, 80%, 65%
and 30% in Stage I,
Stage II, Stage III
and Stage IV
respectively
52 50 2
Popovic (11) Male Breast Cancer in the
era of modern therapies:
serbian since centre
experience report
2014 The Breast
Journal
44 NA 43% 79% 79%
Eryilmaz (12) Male breast cancer:
a retrospective study
of 15 years
2012 J BUON 25 67 er - 60%, PR/HER2
in 40$/2%
72% MRM
(18patients),
2 patients
toilet Bilat
mastectomy
56% SNLB,
84% had SNLD
2013 86 62 NA NA 65.80%
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Selcukbiricik
(13)
Male Breast Cancer:
37-Year Data Study
at a Single Experience
Centre in Turkey
Journal of
Breast Cancer
71% MRM,
2% Simple
mastectomy
13% lumpectomy
axillary
dissection (BCS)
El-Beshbeshi
(14)
Male Breast Cancer:
10-Year Experience at
Mansoura University
Hospital in Egypt
2012 Cancer
Biol Med.
37 57.7 94.6% invasive
ductal ca
91.8% surgery MRM 54%
Sas-Korczynska
(15)
The biological markers
and results of treatment
in male breast cancer
patients. The Cracow
experience.
2014 Neoplasma 32 62.7 4)% T3-T4 78.10% NA 96.8% mastectomy 3.2% tumerectomy þ Axillary
lymphadenoectomy
De Ieso(16) Male breast cancer:
A 30 year experience
in South Australia
2010 Asia Paciﬁc
Journal of
Clinical
Oncology
63 62.07 63.5% had
endocrine therapy
85% 88.90% 8% Sentinal
biopsy
Stierer (17) Male Breast Cancer:
Austian Experience
1995 World J Surg 63 63 ER 78%, PR 70% 62% 147 Total Mast - 7%,
MRM 40%, Radical 4%
Gough (18) A 50 year experience
of male breast cancer:
is outcome changing
1993 Surgical
Oncology
124 62.5 95% invasive
ductal carcinoma
47% 92% Mastectomy 92% mastecomty 41% radical,
39% modiﬁed
radical, 12% simple
Engin (19) Cancer of the Male
Breast: The Turkish
Experience
1993 Journal of
Surgical
Oncology
26 60 92% invasive
ductal carcinoas
27% 81% Unilateralmastectomy NA
Simon (20) Racial differences in
cancer of the male
breast - 15 year
experience in the
detroit metropolitan
area
1992 Breast Cancer
Research &
Treatment
244 64.9 46% invasive
ductal carcinoma
NA 223, 59.6% MRM,
17.1% Simple mastectomy,
15.7% Radical mastectomy,
7.6% partial mastectomy
1. Shah P, Robbani I, Shah O. Clinicopathological study of male breast carcinoma: 24 years of experience. Ann Saudi Med. 2009; 29(4):288e93.
2. Pemmaraju N, Munsell MF, Hortobagyi GN, Giordano SH. Retrospective review of male breast cancer patients: analysis of tamoxifen-related side-effects. Ann Oncol. 2012; 23(6):1471e4.
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volves a large prospective outcomes trial is underway (EORTC trial
10,085 Male BC). This kind of large scale initiative will no doubt
improve our understanding of the treatment of this pathology. The
EORTC collaboration has attempted to overcome the challenges
with prospective trial data collection by implementing an online
data input system. Although it is difﬁcult to quantify the number of
participating institutions, potentially this system encourages a
broader data capture. However this collaboration has succeeded in
moving the research intomale breast cancer towards the ﬁeld of big
data. This potentially will aggregate known information from all
aspects of the disease into models that allow continual improve-
ment and amalgamation in order to improve understanding and
hypothesis generation.
The discussion of the surgical management of male breast
cancer has focused on either discussing novel surgical approaches
or on outcome data on radical mastectomy versus breast
conserving surgery (Table 4). Our literature review identiﬁed 11
publications that discussed the surgical management of male
breast cancer. Two papers present case studies of new techniques
for breast conserving surgery, whilst one case study reports the use
of a simplemastectomy under local anaesthetic for an obese patient
with a symptomatic Aortic aneurysm. One paper discussed the
beneﬁts of fat grafting for male breast reconstruction. These cases
demonstrate the paradigm shift amongst surgeons to adopt breast
conserving techniques equivalent to those utilised in female breast
cancer patients. One article investigates men's attitudes towards
breast conserving surgery, particularly in their concerns over
maintaining some ‘aesthetic’ functional breast and pectoralis shape
post operatively. This is interesting as it reﬂects the similarities
between women's and men's psychosocial reaction to breast
removal and long term reconstruction [12]. Little has been docu-
mented about the potential need for immediate reconstruction of
male breast cancer. In one case the use of fat grafting was reported
as a potential reconstructive therapy to reconstruct the male pec-
toral proﬁle post mastectomy. Traditionally the male mastectomy
does not leave such a large tissue defect compared to female pa-
tients. This is due to the small amount of inherent breast tissue. In
cases where resection has involved some part of the chest wall, ﬂap
based reconstruction can be utilised as volume replacement. More
frequently patients undergo nipple reconstruction and tattooing to
provide visual balance to the chest. Recent data published in 2016
shows that for early stage male breast cancer, breast conserving
surgery yields comparable cause speciﬁc survival rates to modiﬁed
radical mastectomy [13e17]. Such data may support a paradigm
shift away from larger radical procedures, as was seen in female
breast cancer over two decades ago. This data is corroborated by
previous work published by Cloyd and colleagues from 6039 cases.
They utilised the Surveillance, Epidemiology, and End results Pro-
gram (SEER database) and highlighted a change in practice during
the study period, particularly towards the latter end. They
demonstrated a greater proportion of patients undergoing lump-
ectomy over mastectomy. Nguyen presented 9 cases of male breast
cancer in whom patients demanded breast conserving surgery.
Surgical options for male breast reconstruction potentially need
to be low volume and provide the anatomic proﬁle of the male
chest. The deep inferior epigastric perforator ﬂap or the transverse
abdominis muscle (TRAM) ﬂap are also potential options, particu-
larly in patients who may excess fat tissue around the umbilicus.
Due to the rates of donor site morbidity and abdominal herniation
with the TRAM, the DIEP may be a more favoured option. However
such ﬂaps may be preferred for reconstruction of larger volume
defects. The latissimus dorsi is also an option for reconstruction
amongst female patients. It could provide a low volume local ﬂap
option for male patients, however it may compromised somedegree of function in the upper extremity girdle. Techniques from
chest wall reconstruction may be compromised anatomically or too
aggressive for the low volume tissue deﬁcit that remains after
tumour excision.
Currently, techniques such as liposuction that are adopted for
gynaecomastia are precluded as they disrupt the tissue that pre-
vents its histopathological analysis. The peri-areolar approach with
surgical removal of the remnant areola tissue remains a common
technique amongst plastic surgeons for this condition. Further
development of the liposuction device may allow removal of breast
tissue without lysis of the cells that are required for histopatho-
logical analysis [18e20]. This approach could provides adequate
clearance and optimal aesthetic results. It may also be more con-
servative than a formal mastectomy, however at the moment this is
merely a future direction [21].
There are signiﬁcant limitations to small case series. Firstly the
small size precludes any meaningful statistical analysis. Secondly
the disparity between data collection of case sets makes direct
comparison to other centres difﬁcult. However such weaknesses
strengthen the argument for an open access free registry for
recording the epidemiology and surgical outcomes of such a patient
group to facilitate larger scale analysis.
5. Conclusions
This case series and literature review has highlighted the low
incidence of male breast cancer and the inherent difﬁculties in
investigating it as a disease state. Our literature review draws
attention to the number of podium presentations that focus on
single centre experience of male breast cancer. Such presentations
are not obligated to rec. There is currently no platform for such
clinical data to record their ﬁndings in international data registries
that would improve understanding. Despite the efforts of the
EORTC e BIG e NABSG collaboration in collecting prospective data,
an open access clinical case registry would enable the pooling of
case experience from smaller centres for review.
Lastly it would ultimately allow a greater understanding of the
surgical options employed by different centres and their overall
success rates. It would enable, for the ﬁrst time, a speciﬁc set of
guidelines for the surgical management of male breast cancer and
its reconstruction.
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